Immune-Onc, University of Texas discover new AML target

A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE